BRIMONIDINE TARTRATE
OPHTHALMIC SYMPATHOLYTIC AGENTS · OCULAR HYPERTENSION ·+1
Upsher-Smith Laboratories
Drug class
Ophthalmic Antiglaucoma Agents
Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss. Read more about Ophthalmic Antiglaucoma Agents
172 drugs in this class 59 manufacturers
Drugs in Ophthalmic Antiglaucoma Agents
Filter & compare in the drug finder →
Opens the drug finder with Ophthalmic Antiglaucoma Agents preselected. Add indication or manufacturer filters there.
Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss.
These agents achieve ocular hypotension primarily by decreasing aqueous humor production, increasing trabecular or uveoscleral outflow, or combining both pathways through mechanisms that include prostaglandin analogues, beta-adrenergic antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, and Rho kinase inhibitors.
They serve as the primary pharmacologic therapy for managing open-angle glaucoma, ocular hypertension, and select secondary glaucomas, as well as adjunctive medical stabilization in angle-closure glaucoma.
-
drugs.com
Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss
-
nih.gov
Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss These agents achieve ocular hypotension primarily by decreasing aqueous humor production, increasing trabecular or uveoscleral outflow, or combining both pathways through mechanisms that include prostaglandin analogues, beta-adrenergic antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, and Rho...
-
nih.gov
These agents achieve ocular hypotension primarily by decreasing aqueous humor production, increasing trabecular or uveoscleral outflow, or combining both pathways through mechanisms that include prostaglandin analogues, beta-adrenergic antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, and Rho kinase inhibitors
-
nih.gov
They serve as the primary pharmacologic therapy for managing open-angle glaucoma, ocular hypertension, and select secondary glaucomas, as well as adjunctive medical stabilization in angle-closure glaucoma
-
rxlist.com
They serve as the primary pharmacologic therapy for managing open-angle glaucoma, ocular hypertension, and select secondary glaucomas, as well as adjunctive medical stabilization in angle-closure glaucoma
-
openstax.org
They serve as the primary pharmacologic therapy for managing open-angle glaucoma, ocular hypertension, and select secondary glaucomas, as well as adjunctive medical stabilization in angle-closure glaucoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.